Cemiplimab vs Nivolumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03088540 · Phase 3 · completed

This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.

Next expected readout: December 2026 · NCT06623656 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)

Result source: NCT03088540

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemiplimabNivolumab
PFS, median6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
OS, median21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
ORR43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Duration of response, median16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
11 vs 7+4 vs placebon 275NCT03117049
12 other results

PFS, median

Cemiplimab
6.3 vs 5.3vs Chemotherapyn 357NCT03088540
3 other results
Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results

OS, median

Cemiplimab
21.1 vs 12.9+8.2 vs placebon 312NCT03409614
3 other results
Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results

ORR

Cemiplimab
43.6% vs 22.1%+21.5 vs placebon 312NCT03409614
3 other results
  • 42.3% vs 21.4% n 357 · Phase 3 · secondary NCT03088540
  • 40.7% vs 28.3% n 108 · Phase 3 · secondary NCT03409614
  • 36.7% vs 28.3% n 109 · Phase 3 · secondary NCT03409614
Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059

Duration of response, median

Cemiplimab
16.4 vs 7.3+9.1 vs placebon 136NCT03409614
3 other results
Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Cemiplimab: 5 of 5 rows · Nivolumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimab
Rows use multiple source trials
Nivolumab
Rows use multiple source trials
Overall Survival
absolute value · percentage points
41% (n=108) vs 26.5% (n=106) Chemotherapy @ 104wka,b,c
NCT03409614 · Phase 3 · combination
show 2 more doses
42.3% (n=109) vs 26.5% (n=106) Chemotherapy @ 104wk
NCT03409614 · Phase 3 · combination
43.9% (n=312) vs 27.7% (n=154) placebo @ 104wk
NCT03409614 · Phase 3 · combination
23% (n=135) vs 8% (n=137) Docetaxel @ 104wkb,c
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Dropout rate
79%Cemiplimabd
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
90.7%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
90.1%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.3%Cemiplimabd
NCT03088540 · Phase 3
show 10 more results
—Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
0%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
0%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
0.3%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
—30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Serious AEs
36.8%Cemiplimabd
NCT03088540 · Phase 3
show 10 more results
27.1%Extended Treatment: Cemiplimab + C
NCT03088540 · Phase 3 · combination
35.2%Part 1: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi
NCT03409614 · Phase 3 · combination
30.4%Part 2: Cemiplimab + Chemotherapy
NCT03409614 · Phase 3 · combination
33.3%30 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
33.3%480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
d
anaemia 19.7%
decreased appetite 13.8%
fatigue 13.5%
NCT03088540 · Phase 3
show 10 more results
anaemia 31.8%
alopecia 22.4%
diarrhoea 18.8%
NCT03088540 · Phase 3 · combination
anaemia 48.1% (placebo 39.9%)
neutropenia 28.7% (placebo 12.4%)
alopecia 27.8% (placebo 43.8%)
NCT03409614 · Phase 3 · combination
anaemia 33.9% (placebo 39.9%)
nausea 28.4% (placebo 16.3%)
fatigue 21.1% (placebo 8.5%)
NCT03409614 · Phase 3 · combination
anaemia 44.2% (placebo 39.9%)
alopecia 37.5% (placebo 43.8%)
nausea 25.3% (placebo 16.3%)
NCT03409614 · Phase 3 · combination
30 mg/kg
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
480 mge
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context differs: monotherapy versus combination.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cemiplimab

EORTC QLQ-C30 GHS 4.92 vs 0.45 Chemotherapy score @ 3wk
absolute change · score
Cycle 2, Day 1 (C2D1)
NCT03088540 · Phase 3
show 2 more results
2.13 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
1.58 vs 0.92 Chemotherapy score @ 3wk
Cycle 2, Day 1 (C2D1)
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 7.23 vs 1.25 Chemotherapy score @ 6wk
absolute change · score
C3D1
NCT03088540 · Phase 3
show 3 more results
4.65 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
2.75 vs 2.16 Chemotherapy score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
0.96 vs 2.8 placebo score @ 6wk
C3D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.13 vs 2.43 Chemotherapy score @ 9wk
absolute change · score
C4D1
NCT03088540 · Phase 3
show 3 more results
6.22 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
3 vs 2.67 Chemotherapy score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
1.92 vs 4.09 placebo score @ 9wk
C4D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 8.27 vs 1.88 Chemotherapy score @ 12wk
absolute change · score
C5D1
NCT03088540 · Phase 3
show 3 more results
3.31 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
4.72 vs 0.32 Chemotherapy score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
3.35 vs 2.28 placebo score @ 12wk
C5D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 9.64 vs 3 Chemotherapy score @ 15wk
absolute change · score
C6D1
NCT03088540 · Phase 3
show 3 more results
5.63 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.38 vs -1.7 Chemotherapy score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
3.42 vs 2.89 placebo score @ 15wk
C6D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.19 vs 2.55 Chemotherapy score @ 24wk
absolute change · score
C9D1
NCT03088540 · Phase 3
show 3 more results
6.87 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
1.8 vs -3.79 Chemotherapy score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
3.65 vs 2.02 placebo score @ 24wk
C9D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 11.11 vs -4.17 Chemotherapy score @ 33wk
absolute change · score
C12D1
NCT03088540 · Phase 3
show 3 more results
4.44 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
9.15 vs -3.57 Chemotherapy score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
2.37 vs 3.54 placebo score @ 33wk
C12D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.88 vs 5.36 Chemotherapy score @ 42wk
absolute change · score
C15D1
NCT03088540 · Phase 3
show 3 more results
7.35 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
9.4 vs -5.56 Chemotherapy score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
6.23 vs 6.61 placebo score @ 42wk
C15D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.1 vs -3.03 Chemotherapy score @ 51wk
absolute change · score
C18D1
NCT03088540 · Phase 3
show 3 more results
6.73 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
14.44 vs -3.33 Chemotherapy score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
5.28 vs 10.09 placebo score @ 51wk
C18D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 13.42 vs -1.19 Chemotherapy score @ 60wk
absolute change · score
C21D1
NCT03088540 · Phase 3
show 3 more results
11.36 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
15.71 vs 0 Chemotherapy score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
6.07 vs 18.59 placebo score @ 60wk
C21D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 10.76 vs 1.19 Chemotherapy score @ 69wk
absolute change · score
C24D1
NCT03088540 · Phase 3
show 3 more results
8.33 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
14.29 vs -11.11 Chemotherapy score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
5.05 vs 10.83 placebo score @ 69wk
C24D1
NCT03409614 · Phase 3 · combination
EORTC QLQ-C30 GHS 12.5 vs -3.33 Chemotherapy score @ 78wk
absolute change · score
C27D1
NCT03088540 · Phase 3
show 3 more results
8.89 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
19.05 vs -22.22 Chemotherapy score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination
5.27 vs 8.33 placebo score @ 78wk
C27D1
NCT03409614 · Phase 3 · combination

+ 35 further endpoints in the CSV export.

Nivolumab

Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
LCSS Symptom Deterioration 31.3% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
ratio to baseline · % of baseline
NCT02477826 · Phase 3 · combination
show 5 more results
35.4% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3
33.2% (n=187) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
28.8% (n=177) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
30% (n=377) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
23% (n=126) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
NSCLC-SAQ Total -0.6 vs -0.89 Durva score @ 48wk
absolute change · score
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.91 vs -0.89 Durva score @ 48wk
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Disease Control 87.3% (n=275) vs 89.8% (n=275) placebo
responder rate · % of participants
NCT03117049 · Phase 3 · registry result, not featured evidence
Complete 5.1% (n=275) vs 2.9% (n=275) placebo
responder rate · % of participants
Complete response
NCT03117049 · Phase 3 · registry result, not featured evidence · converted to % from 14 Participants as posted
Partial 56.4% (n=275) vs 47.6% (n=275) placebo
responder rate · % of participants
Partial response
NCT03117049 · Phase 3 · registry result, not featured evidence · converted to % from 155 Participants as posted

+ 36 further endpoints in the CSV export.

Melanoma

Shared mechanism: PD-1 · full Melanoma pipeline

Cemiplimab

Marketed by Regeneron Pharmaceuticals and partners

Phase 3 in Melanomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT05608291 (registry estimate)

No aligned efficacy figure on record for this race.

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Melanomamonoclonal antibody
Partial signal

NCT01721746 · Phase 3 · completed

This was a large randomized trial against chemotherapy, but it was open-label. Overall survival, an objective outcome, was not significantly better with nivolumab, although more patients had a tumour response.

Next expected readout: November 2026 · NCT06712927 (registry estimate)

Reported efficacy

Recurrence-free Survival (RFS) (up to 36 months): Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) (met)

Result source: NCT02388906

Results for Melanoma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Cemiplimab: 3 of 4 rows · Nivolumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCemiplimabNivolumab
Dropout rate
0%30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
0%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
0%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
0%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—Pixatimod (PG545) + Nivolumab + Cya
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
100%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
97.5%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
100%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
0%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
99.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
96.5%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
85.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
100%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
—20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
—10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
—Pixatimod (PG545) + Nivolumab + Cya
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
—Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
—280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
—140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
33.3%30 mg/kga
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
40%20 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
23.8%20 mg/kg in combination with cemiplimab
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
11.1%10 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
25%3 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
60%1 mg/kg
NCT05259696 · Phase 1/2 · registry result, not featured evidence
37.5%Pixatimod (PG545) + Nivolumab + Cya
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 66 more results
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
57.1%40 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
85.7%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
49.4%30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
33.3%20 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
100%400 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
83.3%BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
—BMS-986205 400 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
68.8%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
82.4%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
64.3%BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
66.7%BMS-986205 100 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
85.7%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
83.3%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
80%BMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
100%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
60%BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence
71.4%BMS-986205 25 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50%Food Effect/ Relative BA (FE BA) S
NCT02658890 · Phase 1/2 · registry result, not featured evidence
58.8%Part 2: Exp ML Anti-PDL1+CTLA4
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 2: Exp ML BRAF-MT- NIVO
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0%0.3 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.1 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.03 mg/kg + Nivolumab
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
47.2%Cohort 1(Arm)/ inNSCLC (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
15.8%Cohort 2(Arm)/ PD1-MM (Phase 2) -
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
42.9%Cohort 3A(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
46.4%Cohort 3B(Arm)/ PD1-NSCLC (Phase 2
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
40%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
60%3.2/4 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
51.3%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
47.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
56.1%1.6/2 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
55.6%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.8/ 1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
66.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
16.7%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
57.1%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
100%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
20%0.8/1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
—0.4/ 0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
40%0.4/0.5 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
33.3%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
0%0.2/0.25 mg
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
75%0.08/0.1 mg
NCT02009449 · Phase 1 · registry result, not featured evidence
14.3%280 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
0%140 mg / 280 mg
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
66.7%140 mg PO BID
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
100%140 mg PO daily
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
30 mg/kga
infusion related reaction 66.7%
anaemia 33.3%
abdominal pain 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
show 5 more results
20 mg/kg
infusion related reaction 66.7%
anaemia 40%
constipation 26.7%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
20 mg/kg in combination with cemiplimab
infusion related reaction 42.9%
cough 33.3%
fatigue 33.3%
NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination
10 mg/kg
infusion related reaction 55.6%
fatigue 33.3%
dehydration 22.2%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
3 mg/kg
abdominal pain 25%
arthralgia 25%
back pain 25%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
1 mg/kg
abdominal pain 60%
nausea 60%
vomiting 40%
NCT05259696 · Phase 1/2 · registry result, not featured evidence
a
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 63 more results
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
40 mg
anaemia 57.1%
decreased appetite 57.1%
contusion 42.9%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 71.4%
weight decreased 71.4%
anaemia 57.1%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
30 mg
fatigue 65.8%
nausea 55.7%
diarrhoea 53.2%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
20 mg
diarrhoea 66.7%
dyspnoea 66.7%
fatigue 66.7%
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
400 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 400 mg + nivolumab 240 mg
constipation 66.7%
fatigue 66.7%
vomiting 66.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg + nivolumab 240 mg
fatigue 66.7%
nausea 44.4%
vomiting 44.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
decreased appetite 43.8%
fatigue 43.8%
nausea 43.8%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 52.9%
alanine aminotransferase increased 35.3%
urinary tract infection 35.3%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 200 mg
fatigue 42.9%
constipation 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg + nivolumab 240 mg
fatigue 58.3%
anaemia 50%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
asthenia 28.6%
decreased appetite 28.6%
nausea 28.6%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 55.6%
nausea 50%
vomiting 38.9%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
BMS-986205 100 mg
decreased appetite 33.3%
asthenia 26.7%
constipation 26.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
headache 100%
oedema peripheral 100%
vomiting 100%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 50 mg + nivolumab 240 mg
fatigue 70%
vomiting 60%
decreased appetite 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
50 mg
abdominal discomfort 0%
abdominal distension 0%
abdominal hernia 0%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
BMS-986205 25 mg + nivolumab 240 mg
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 64.3%
nausea 42.9%
diarrhoea 35.7%
NCT02658890 · Phase 1/2 · registry result, not featured evidence
constipation 29.4%
fatigue 29.4%
nausea 29.4%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 50%
fatigue 50%
headache 50%
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
0.3 mg/kg + Nivolumab
chills 100%
nausea 100%
pruritus 100%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.1 mg/kg + Nivolumab
anaemia 66.7%
chills 66.7%
decreased appetite 66.7%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
0.03 mg/kg + Nivolumab
fatigue 100%
anxiety 33.3%
arthralgia 33.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 56.6%
pyrexia 52.8%
nausea 45.3%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
pyrexia 68.4%
chills 50%
nausea 47.4%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
nausea 50%
pyrexia 50%
dyspnoea 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
chills 46.4%
asthenia 42.9%
pyrexia 42.9%
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.2/4 mg
anaemia 80%
decreased appetite 80%
fatigue 80%
NCT02009449 · Phase 1 · registry result, not featured evidence
3.2/4 mg
fatigue 100%
anaemia 80%
headache 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 75.2%
fatigue 59%
thrombocytopenia 59%
NCT02009449 · Phase 1 · registry result, not featured evidence
1.6/2 mg
fatigue 85.3%
anaemia 76.5%
thrombocytopenia 58.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
1.6/2 mg
anaemia 68.4%
fatigue 59.6%
cough 42.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
constipation 66.7%
decreased appetite 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.8/1 mg
fatigue 88.9%
nausea 83.3%
anaemia 77.8%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
thrombocytopenia 66.7%
fatigue 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 83.3%
fatigue 66.7%
thrombocytopenia 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 100%
decreased appetite 66.7%
lipase increased 50%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
fatigue 85.7%
thrombocytopenia 71.4%
anaemia 57.1%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
activated partial thromboplastin time prolonged 100%
alanine aminotransferase increased 100%
anaemia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.8/1 mg
anaemia 100%
fatigue 100%
thrombocytopenia 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
anaemia 83.3%
fatigue 83.3%
nausea 83.3%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.4/0.5 mg
anaemia 100%
dyspnoea 66.7%
fatigue 66.7%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
thrombocytopenia 100%
fatigue 66.7%
anaemia 33.3%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.4/0.5 mg
fatigue 100%
anaemia 80%
hypokalaemia 60%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.2/0.25 mg
anaemia 50%
fatigue 50%
injection site erythema 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
0.2/0.25 mg
asthenia 100%
neutropenia 100%
spermatic cord disorder 100%
NCT02009449 · Phase 1 · registry result, not featured evidence · combination
0.08/0.1 mg
injection site erythema 75%
abdominal distension 50%
abdominal pain 50%
NCT02009449 · Phase 1 · registry result, not featured evidence
280 mg PO BID
aspartate aminotransferase increased 14.3%
cough 14.3%
fatigue 14.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg / 280 mg
anemia 66.7%
back pain 66.7%
diarrhea 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO BID
lipase increased 66.7%
alkaline phosphatase increased 33.3%
anorexia 33.3%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination
140 mg PO daily
hepatobiliary disorders - other, specify 100%
abdominal pain 66.7%
back pain 66.7%
NCT03229278 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Stable Disease 40% (n=5)
absolute value · percentage points
No placebo or comparator arm
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
37.5% (n=8)
Stable Disease (SD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
Progressive Disease 60% (n=5)
absolute value · percentage points
No placebo or comparator arm
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
62.5% (n=8)
Progressive Disease (PD)
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 6mo 20% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 12mo 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
13% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
PFS 18.37 months30 mg
time to event · months
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 79.6 weeks as posted
show 8 more results
2.33 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 10.1 weeks as posted
3.37 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 14.6 weeks as posted
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
2 months
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
4.11 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
1.97 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.43 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
3.65 months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
OS 6mo 75% (n=5) @ 24wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=8) @ 24wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 0% (n=5) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
19% (n=8) @ 52wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
OS24 0% (n=5) @ 104wk
absolute value · percentage points
No placebo or comparator arm
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0% (n=8) @ 104wk
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
ORR 56.6% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
22.7% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 84.9% (n=53)30 mg
absolute value · percentage points
No placebo or comparator arm
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
68.2% (n=22)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
66.7% (n=6)30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 30.96 monthsBMS-986205 200 mg
time to event · months
No placebo or comparator arm
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 134.14 weeks as posted
show 14 more results
17.57 months*BMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 76.14 weeks as posted
NA monthsBMS-986205 200 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 200 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
NA monthsBMS-986205 100 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
12.03 months*BMS-986205 50 mg + nivolumab 240 mg
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 52.14 weeks as posted
NA months30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination
7.38 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted
20.63 months*30 mg
NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted
NA months
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination
12.72 months*
NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 55.14 weeks as posted
NA months
NCT02658890 · Phase 1/2 · registry result, not featured evidence
NA months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination
NA months
NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Nivolumab's landscape